ICU Medical (ICUI) Set to Announce Quarterly Earnings on Tuesday

ICU Medical (NASDAQ:ICUI) is set to issue its quarterly earnings data after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of $0.84 per share for the quarter. ICU Medical has set its FY24 guidance at $4.40-5.10 EPS and its FY 2024 guidance at 4.400-5.100 EPS.Parties that are interested in registering for the company’s conference call can do so using this link.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Tuesday, February 27th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.39. ICU Medical had a negative net margin of 1.31% and a positive return on equity of 6.35%. The firm had revenue of $587.86 million for the quarter, compared to the consensus estimate of $564.77 million. On average, analysts expect ICU Medical to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

ICU Medical Stock Performance

Shares of NASDAQ ICUI opened at $99.99 on Friday. The company’s fifty day moving average price is $100.98 and its 200 day moving average price is $97.28. ICU Medical has a 1 year low of $78.28 and a 1 year high of $212.43. The company has a market capitalization of $2.44 billion, a PE ratio of -81.29 and a beta of 0.72. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.06 and a current ratio of 2.53.

Wall Street Analyst Weigh In

Separately, KeyCorp increased their price objective on shares of ICU Medical from $134.00 to $136.00 and gave the company an “overweight” rating in a report on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $123.00.

Insider Activity

In other news, COO Christian B. Voigtlander sold 13,603 shares of the stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $107.19, for a total value of $1,458,105.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, COO Christian B. Voigtlander sold 13,603 shares of the firm’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $107.19, for a total transaction of $1,458,105.57. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel Woolson sold 791 shares of the firm’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $98.27, for a total transaction of $77,731.57. Following the sale, the vice president now owns 13,980 shares of the company’s stock, valued at $1,373,814.60. The disclosure for this sale can be found here. Insiders sold 24,262 shares of company stock worth $2,545,532 over the last three months. Insiders own 6.70% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.